Renalytix reported $2.3 million in revenue, including $2.1 million from testing services and $0.2 million from pharmaceutical services. The loss before tax was $44.9 million, which included impairment of intangibles of $10.2 million and fair value adjustments to convertible debt of $3.75 million. Total assets were $7.3 million, and cash and cash equivalents amounted to $4.7 million.